Just weeks after a stinging report was delivered to Aurobindo’s sterile drug plant in Telangana, the FDA has blasted a finished drug facility there.

An explosion at a pharmaceutical manufacturing facility has again claimed the lives of workers.

Celgene returning tislelizumab rights after Bristol-Myers wraps its buyout would have "marginal" effect, BeiGene Chief Adviser Eric Hedrick said.

Big Pharma's older drugs face pricing pressure in China; Pfizer moves Upjohn HQ to Shanghai; Hansoh Pharma eyes $1 billion Hong Kong IPO.

Two injected drugs manufactured by an Indian company with a history of sterility problems are being recalled because of contamination concerns.

GSK's Shingrix nabs Chinese nod; Roche's Chugai invests $1.15 billion in new R&D site; Japanese authority warns of Verzenio's side effect.

Rumor has it that several companies are in talks to buy Daiichi's over-the-counter drugs business, which could fetch $900 million.

Dendreon has signaled faith in its struggling prostate drug Provenge by signing a 10-year lease extension for its California manufacturing facility.